Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ixiaro + MBJEV is a combination of two Japanese encephalitis vaccines. - **Ixiaro** is an inactivated, adsorbed vaccine derived from the Japanese encephalitis virus (JEV) strain SA14-14-2, produced in Vero cells and formulated with aluminum hydroxide as an adjuvant. It is indicated for active immunization against Japanese encephalitis in individuals aged 2 months and older. The mechanism of action involves inducing neutralizing antibodies against JEV to provide protection from infection[1][3][4][5]. - **MBJEV** refers to the "Mouse Brain-derived Japanese Encephalitis Vaccine," a traditional vaccine prepared by propagating JEV in mouse brain tissue, then inactivating and purifying it. This type of vaccine has been widely used but is being replaced by cell culture-derived vaccines like Ixiaro due to improved safety profiles. This combination would be used for immunization against Japanese encephalitis virus, likely where both types are available or required due to local guidelines or supply issues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ixiaro + MBJEV.